Evidence map›Paper›PMID 29212355›Full record

ArticleThe British journal of radiology2018

The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies.

Claudia Sassi, Marta Stanzani, Russell E Lewis, Giancarlo Facchini, Alberto Bazzocchi, Michele Cavo, Giuseppe Battista

Open access · greenAbstract read
In one paragraph

Article in The British journal of radiology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Atypical imaging patterns during lung invasive mould diseases: lessons for clinicians.European respiratory review : an official journal of the European Respiratory Society · 2023
    Review
  5. Hypodense Sign in Lungs on CT in Immunocompromised Patient.The Indian journal of radiology & imaging · 2023
    Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Claudia Sassi1 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Division of Radiology, S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.ORCID 0000-0002-7864-2586
Marta Stanzani2 Department of Hematology and Oncology, Institute of Hematology "L. e A. Seragnoli", S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.
Russell E Lewis3 Department of Medical and Surgical Sciences, Infectious Diseases Clinics, S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.
Giancarlo Facchini1 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Division of Radiology, S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.
Alberto Bazzocchi4 Department of Diagnostic and Interventional Radiology, "Rizzoli" Orthopaedic Institute , Bologna , Italy.
Michele Cavo2 Department of Hematology and Oncology, Institute of Hematology "L. e A. Seragnoli", S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.
Giuseppe Battista1 Department of Experimental, Diagnostic and Specialty Medicine (DIMES), Division of Radiology, S.Orsola-Malpighi Hospital, University of Bologna , Bologna , Italy.
Policlinico S.Orsola-Malpighi · ITUniversity of Bologna · ITIstituto Ortopedico Rizzoli · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveThe hypodense sign (HyS) on CT imaging is highly suggestive of pulmonary invasive mould disease (IMD) in patients with haematological malignancies, but its diagnostic utility has not been systematically evaluated on contrast-enhanced CT. The objective of this study was to compare the diagnostic performance of the HyS to other common CT findings in a cohort of haematology patients with proven, probable or possible IMD based on European Organization for Research and Treatment of Cancer/Mycoses Study Group criteria.

methodsWe analysed the diagnostic performance of the HyS to other common CT signs among 127 neutropenic patients with haematological malignancies submitted to both non-contrast-enhanced and contrast-enhanced CT scans of the lungs, including CT pulmonary angiography.

resultsThe HyS was detected in 15.7% of patients imaged without contrast, and 44.1% after contrast administration. A contrast-aided HyS was detected in 86.6, 78.0 and 15.5% of patients with European Organization for Research and Treatment of Cancer/Mycoses Study Group proven, probable and possible IMD, respectively. When analysed per clinical diagnosis (proven, probable and highly possible IMD-i.e. no alternative diagnosis to mould disease reached), the contrast-enhanced HyS was as sensitive as the halo sign but significantly more specific [halo sign 0.56, 95% CI (0.39-0.71) vs HyS 0.98, 95% CI (0.87-1.00)]. Only the vessel occlusion sign was more sensitive [0.97, 95% CI (0.91-0.99)] and specific [0.97, 95% CI (0.86-0.99)] than the HyS for IMD diagnosis.

conclusionThe high specificity of the HyS strongly supports the diagnosis of pulmonary IMD in neutropenic patients, and is highly suggestive breakthrough fungal disease in patients on mould-active antifungal prophylaxis. Advances in knowledge: This is the first systematic analysis of the hypodense sign on contrast-enhanced CT; the sign can support the diagnosis of IMD when other CT signs are uncertain.

Indexed as

AdultAgedContrast MediaFemaleHematologic NeoplasmsHumansImmunocompromised HostLung Diseases, FungalMaleMiddle AgedRadiography, ThoracicRetrospective StudiesSensitivity and SpecificityTomography, X-Ray ComputedContrast Media

Identifiers

PMID29212355
PMCPMC5965459
OpenAlexW2774093791

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.